Literature DB >> 17290187

Interaction between krit1 and malcavernin: implications for the pathogenesis of cerebral cavernous malformations.

Jun Zhang1, Daniele Rigamonti, Harry C Dietz, Richard E Clatterbuck.   

Abstract

OBJECTIVE: Cerebral cavernous malformations (CCM) are a relatively common autosomal dominant disorder leading to the formation of vascular malformations in the nervous system. Mutations in krit1 and malcavernin, the proteins encoded by the genes at the CCM1 and CCM2 loci, respectively, are responsible for the majority of CCMs. Similar to integrin cytoplasmic domain-associated protein-1alpha, a known krit1 interactor, malcavernin is a phosphotyrosine binding protein. We report here that krit1 also interacts with malcavernin.
METHODS: We used two-hybrid analysis, in vivo coimmunoprecipitation, and epitope mapping to explore the interaction between krit1 and malcavernin. Immunocytochemistry was used to study the cellular localization of these proteins.
RESULTS: We demonstrate that malcavernin independently binds to two of the three NPXY (asparagine, proline, undetermined/variable amino acid, and tyrosine) motifs in krit1. By immunocytochemistry, malcavernin protein is cytoplasmic at steady state, but shuttles between the nucleus and cytoplasm, despite lacking either a nuclear localization signal or a nuclear export signal in its sequence.
CONCLUSION: These data suggest that krit1 interacts with malcavernin through its NPXY motifs and may shuttle it through the nucleus via its nuclear localization signal and nuclear export signals, thereby regulating its cellular function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290187     DOI: 10.1227/01.NEU.0000249268.11074.83

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  43 in total

1.  Ccm1 regulates microvascular morphogenesis during angiogenesis.

Authors:  Huiling Liu; Daniele Rigamonti; Ahmed Badr; Jun Zhang
Journal:  J Vasc Res       Date:  2010-10-07       Impact factor: 1.934

Review 2.  From germline towards somatic mutations in the pathophysiology of vascular anomalies.

Authors:  Nisha Limaye; Laurence M Boon; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 3.  Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction.

Authors:  Eva Faurobert; Corinne Albiges-Rizo
Journal:  FEBS J       Date:  2010-01-22       Impact factor: 5.542

4.  Ccm1 assures microvascular integrity during angiogenesis.

Authors:  Huiling Liu; Daniele Rigamonti; Ahmed Badr; Jun Zhang
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

5.  Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity.

Authors:  Xiaofeng Li; Rong Zhang; Haifeng Zhang; Yun He; Weidong Ji; Wang Min; Titus J Boggon
Journal:  J Biol Chem       Date:  2010-05-19       Impact factor: 5.157

6.  Expression of CCM2 and CCM3 during mouse gonadogenesis.

Authors:  Aylin Yaba; N Ece Gungor Ordueri; Gamze Tanriover; Pinar Sahin; Necdet Demir; Ciler Celik-Ozenci
Journal:  J Assist Reprod Genet       Date:  2015-09-19       Impact factor: 3.412

Review 7.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

8.  ccm2-like is required for cardiovascular development as a novel component of the Heg-CCM pathway.

Authors:  Jonathan N Rosen; Vanessa M Sogah; Lillian Y Ye; John D Mably
Journal:  Dev Biol       Date:  2013-01-15       Impact factor: 3.582

9.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

10.  Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway.

Authors:  Benjamin Kleaveland; Xiangjian Zheng; Jian J Liu; Yannick Blum; Jennifer J Tung; Zhiying Zou; Shawn M Sweeney; Mei Chen; Lili Guo; Min-min Lu; Diane Zhou; Jan Kitajewski; Markus Affolter; Mark H Ginsberg; Mark L Kahn
Journal:  Nat Med       Date:  2009-01-18       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.